Urinary bladder pain is a primary symptom associated with interstitial cystitis/painful bladder syndrome. We used systemic injections of cyclophosphamide (CYP), an alkylating antineoplastic agent, to induce cystitis and examine the roles of 2 channels previously demonstrated to be required for inflammatory visceral hyperalgesia: transient receptor potential vanilloid-1 (TRPV1) and ankyrin-1 (TRPA1). Injection of CYP (100 mg/kg, i.p.) every other day for 5 days was accompanied by bladder edema and urothelial ulceration, but without significant plasma extravasation or infiltration of neutrophils. Toluidine blue staining showed a significant increase in the number of degranulated bladder mast cells after CYP treatment. Despite this mild pathology, CYP-treated mice exhibited bladder hyperalgesia 1 day after the final injection that persisted 7 days later. Although many previous studies of visceral hyperalgesia have reported changes in dorsal root ganglion neuron TRPV1 expression and/or function, we found no change in bladder afferent TRPV1 expression or sensitivity on the basis of the percentage of bladder afferents responsive to capsaicin, including at submaximal concentrations. In contrast, the percentage of bladder afferents expressing functional TRPA1 protein (ie, those responsive to mustard oil) increased $2.5-fold 1 day after CYP treatment, and remained significantly elevated 7 days later. Moreover, bladder hyperalgesia was reversed by acute treatment with the TRPA1 antagonist HC-030031 (300 mg/kg, i.p.). Our results indicate that CYP-induced bladder hyperalgesia can be induced without robust inflammation or changes in primary afferent TRPV1. However, significant changes were observed in TRPA1 expression, and blockade of TRPA1 alleviated CYP-induced bladder hyperalgesia. Ó
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Introduction
Pain originating from the urinary bladder is a cardinal symptom associated with interstitial cystitis (IC)/painful bladder syndrome, the etiology of which appears to be multifactorial, with associated sensory alterations resulting from both peripheral and central changes. The impact of peripheral signaling in generation of bladder pain is underscored by the reduction in pain reported by patients with IC after intravesical treatment with lidocaine or botulinum toxin A [38, 45] .
Transient receptor potential vanilloid-1 (TRPV1) and ankyrin-1 (TRPA1) are ligand-gated, Ca 2+ -permeable cation channels that are requisite mediators of visceral hypersensitivity via regulation of both efferent and afferent function of primary afferent neurons [24, 48, 56] . Both channels are expressed in neuronal and nonneuronal lower urinary tract tissues in humans [14, 41] and rodents [3, 16, 17, 51, 57, 59] . Their importance has been characterized for bladder function, eg, micturition [6, 9, 34] . However, their roles in regulation of in vivo bladder nociception per se have not.
In contrast to bacterial cystitis, IC characteristically occurs in the absence of ongoing infection; it may, however, be accompanied by neurogenic inflammation, mastocytosis, and increased cytokines, of which TRP channels may be upstream mediators or downstream targets [47, 48, 58] . The goal of our experiments was to evaluate the roles of TRPV1 and TRPA1 in bladder afferent sensitization and persistent hyperalgesia. Using a mouse model of CYP-induced cystitis, we quantified and characterized the relationship between changes in visceral nociceptive behavior and TRPV1/TRPA1 channel expression and function in dorsal root ganglion (DRG) bladder afferent neurons. We found that changes in TRPA1 expression and 
